GLP-1 medications have revolutionized weight loss therapy, evolving from niche treatments for diabetes to household names such as Ozempic and Wegovy. As of November 2025, a Kaiser Family Foundation survey indicates that 1 in 8 adults in the U.S. has tried a GLP-1 drug, whether for weight loss, diabetes, or other conditions. The recent availability of Wegovy in pill form is expected to boost these numbers further, making treatment more accessible to a broader population.

Significantly, GLP-1 medications can enable patients to lose between 15% and 20% of their body weight, marking them as one of the most effective non-surgical treatments for obesity. The mechanism behind these drugs involves the action of GLP-1, a hormone released by the intestine that helps regulate blood sugar levels and appetite after meals. By signalling the pancreas to release insulin, these medications assist in managing metabolic conditions alongside weight loss.

As the acceptance and use of GLP-1 medications grow, questions arise about next steps for individuals who have met their weight loss goals. Continued monitoring, lifestyle changes, and possible long-term use of the medications may be necessary to ensure sustained results and maintain health improvements. This shift indicates broader trends in how weight loss and diabetes management are perceived and treated in contemporary health practices, underlining the importance of accessibility and ongoing care.